Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunitiesBarbara Merelli, Mario Mandalà, Daniela Massi et al.|Critical Reviews in Oncology/Hematology|2013Cited by 170
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristicsDaniela Massi, Mario Mandalà, Valentina Audrito et al.|Annals of Oncology|2014Cited by 146
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V. Long, Reinhard Dummer, Axel Hauschild et al.|New England Journal of Medicine|2024Cited by 123